Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Market Drivers : Growth is driven by the rising prevalence of obesity and Type 2 diabetes, the shift toward incretin-based therapies, expanding clinical evidence of weight-loss benefits, and improved patient awareness, supported by physician advocacy and digital health engagement
5,000 to Rs
Comparison of adverse cardiovascular event endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques: A systematic review and meta-analysis
Usually a one-time intervention
On the other hand, improved metabolic health could reduce atrial remodeling, a known contributor to atrial fibrillation
US$ 25.86
US$ 29.58
US$ 27.02
US$ 20.46
US$ 22.84
US$ 22.32
US$ 29.32
US$ 24.08
